Non-[18F]FDG PET in clinical oncology

被引：92
|
作者：
Groves, Ashley M. [1 ]
Win, Thida
Ben Haim, Simona
Ell, Peter J.
机构：
[1] UCL, Inst Nucl Med, London NW1 2BU, England
[2] Lister Hosp, Stevenage, Herts, England
来源：
LANCET ONCOLOGY | 2007年 / 8卷 / 09期
关键词：
D O I：
10.1016/S1470-2045(07)70274-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PET is an exquisitely sensitive molecular imaging technique using positron-emitting radioisotopes coupled to specific ligands. Many biological targets of great interest can be imaged with these radiolabelled ligands. This review describes the current status of non-18-fluorodeoxyglucose PET tracers that have a potential clinical effect in oncology. With the help of these tracers, knowledge is being acquired on the molecular characterisation of specific tumours, their biological signature, and postinterventional response. The potential role of these imaging probes for tumour detection and monitoring is progressively being recognised by clinical oncologists, biologists, and pharmacologists.
引用
收藏
页码：822 / 830
页数：9
相关论文
共 50 条
  • [1] PET in gyneco-oncology, beyond [18F]FDG?
    Chanchou, M.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2023, 47 (04): : 183 - 185
  • [2] Robustness of radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR
    Vuong, D.
    Bogowicz, M.
    Huellner, M.
    Veit-Haibach, P.
    Andratschke, N.
    Unkelbach, J.
    Guckenberger, M.
    Tanadini-Lang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S41 - S41
  • [3] PET and [F-18]-FDG in oncology: A clinical update
    Conti, PS
    Lilien, DL
    Hawley, K
    Keppler, J
    Grafton, ST
    Bading, JR
    NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (06) : 717 - 735
  • [4] [18F]FDG PET/CT outperforms [18F]FDG PET/MRI in differentiated thyroid cancer
    Vrachimis, Alexis
    Burg, Matthias Christian
    Wenning, Christian
    Allkemper, Thomas
    Weckesser, Matthias
    Schaefers, Michael
    Stegger, Lars
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (02) : 212 - 220
  • [5] [18F]FDG PET/CT outperforms [18F]FDG PET/MRI in differentiated thyroid cancer
    Alexis Vrachimis
    Matthias Christian Burg
    Christian Wenning
    Thomas Allkemper
    Matthias Weckesser
    Michael Schäfers
    Lars Stegger
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 212 - 220
  • [6] Robustness study on radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR
    Vuong, D.
    Bogowicz, M.
    Huellner, M.
    Veit-Haibach, P.
    Andratschke, N.
    Unkelbach, J.
    Guckenberger, M.
    Tanadini-Lang, S.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S1159 - S1159
  • [7] Interchangeability of radiomic features between [18F]-FDG PET/CT and [18F]-FDG PET/MR
    Diem Vuong
    Tanadini-Lang, Stephanie
    Huellner, Martin W.
    Veit-Haibach, Patrick
    Unkelbach, Jan
    Andratschke, Nicolaus
    Kraft, Johannes
    Guckenberger, Matthias
    Bogowicz, Marta
    MEDICAL PHYSICS, 2019, 46 (04) : 1677 - 1685
  • [8] Clinical application of [18F]FDG PET/CT in follicular lymphoma
    Diaz-Silvan, A.
    Oton-Sanchez, L. F.
    Caresia-Aroztegui, A. P.
    Cozar-Santiago, M. del Puig
    Orcajo-Rincon, J.
    De Arcocha-Torres, M.
    Delgado-Bolton, R. C.
    Cabello-Garcia, D.
    SociedadEspa, Sociedad Espanola de Medicina Nuclear e Imagen Molecular
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2022, 41 (03): : 202 - 212
  • [9] Clinical Relevance of [18F]Florbetaben and [18F]FDG PET/CT Imaging on the Management of Patients with Dementia
    Librizzi, Damiano
    Cabanel, Nicole
    Zavorotnyy, Maxim
    Riehl, Elisabeth
    Kircher, Tilo
    Luster, Markus
    Hooshyar Yousefi, Behrooz
    MOLECULES, 2021, 26 (05):
  • [10] Staging with [18F]FDG PET/CT
    Iqbal, Ramsha
    Aras, Tuba
    Mammatas, Lemonitsa
    Vogel, Wouter V.
    Oprea-Lager, Daniela E.
    Verheul, Hendrik M.
    Boellaard, Ronald
    van Oordt, Catharina W. Menke-van der Houven
    CANCER RESEARCH, 2019, 79 (13)
12345